Black Friday Savings ! Exclusive Deals on Latest Pharma and Medical Technology Reports.

Explore Now

Acute Pyelonephritis Pipeline Insight

DelveInsight’s, “Acute Pyelonephritis – Pipeline Insight, 2021,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Acute Pyelonephritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Acute Pyelonephritis Understanding

Acute Pyelonephritis: Overview

Acute pyelonephritis is a bacterial infection causing inflammation of the kidneys and is one of the most common diseases of the kidney. Pyelonephritis occurs as a complication of an ascending urinary tract infection (UTI) which spreads from the bladder to the kidneys and their collecting systems. The main cause of acute pyelonephritis is gram-negative bacteria, the most common being Escherichia coli. Other gram-negative bacteria which cause acute pyelonephritis include Proteus, Klebsiella, and Enterobacter. Young sexually active women are most often affected by acute pyelonephritis. Groups with extremes of age such as the elderly and infants are also at risk due to abnormalities in anatomy and changes in hormones.


Symptoms usually appear within two days of infection. Common symptoms include:

  • Pain in the abdomen
  • Pus or blood in the urine
  • Frequent urination
  • Painful or burning urination
  • Fever,chills
  • Nausea, vomiting


History and physical examination are the most useful tools for diagnosis. A positive urinalysis confirms the diagnosis with a compatible history and physical examination. Imaging test: CT scan, MRI, ultrasound and radioactive imaging are recommended for the diagnosis of Acute Pyelonephritis. Dimercaptosuccinic acid (DMSA) scan is mainly used for detailed renal cortical, to detect scarring.


Antibiotics are the first course of action against acute pyelonephritis. The antibiotic options are: levofloxacin, ciprofloxacin, co-trimoxazole, ampicillin. Surgery may rarely be required to drain renal or perinephric abscesses, or to relieve obstructions causing the infection

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Acute Pyelonephritis R&D. The therapies under development are focused on novel approaches to treat/improve Acute Pyelonephritis.

Acute Pyelonephritis Emerging Drugs Chapters

This segment of the Acute Pyelonephritis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Acute Pyelonephritis Emerging Drugs

Tebipenem Pivoxil Hydrobromide: Spero Therapeutics

Spero’s lead product candidate, tebipenem HBr, is being developed as the first oral carbapenem antibiotic for use in complicated urinary tract infection and acute pyelonephritis. In September 2020, tebipenem HBr completed a pivotal Phase 3 trial, ADAPT-PO, for the treatment of cUTI including acute pyelonephritis (AP). If approved, tebipenem HBr would be the first oral carbapenem antimicrobial to receive marketing approval in the United States. Tebipenem HBr has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designations by the FDA for the treatment of cUTI and Acute Pyelonephritis.

Cefepime: Venatorx Pharmaceuticals, Inc.

Venatorx is currently enrolling a Phase 3 clinical trial of cefepime-taniborbactam in patients with complicated urinary tract infections (cUTIs) including Acute Pyelonephritis. Venatorx believes that taniborbactam, in a fixed combination with the fourth generation cephalosporin, cefepime, has the potential to provide a valuable broad-spectrum treatment option.

ETX2514SUL: Entasis Therapeutics

Entasis Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, reported positive topline results from the company’s multi-national Phase 2 clinical trial of its β-lactamase inhibitor, ETX2514, in combination with sulbactam (the combination referred to as ETX2514SUL) in the treatment of complicated urinary tract infections acute pyelonephritis (kidney infection) in adults and complicated urinary tract infections. The results of the Phase 2 trial support progression of ETX2514SUL into Phase 3, an important next step in developing pathogen-targeted products against drug-resistant bacterial infections.

Further product details are provided in the report……..

Acute Pyelonephritis: Therapeutic Assessment

This segment of the report provides insights about the different Acute Pyelonephritis drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Acute Pyelonephritis

There are approx. 10+ key companies which are developing the therapies for Acute Pyelonephritis. The companies which have their Acute Pyelonephritis drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Spero Therapeutics and others.


DelveInsight’s report covers around 10+ products under different phases of clinical development like

  • Late-stage products (Phase III )
  • Mid-Stage products (Phase II)
  • Early-stage products ( Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Acute Pyelonephritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intravenous
  • Oral
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Small molecules
  • Peptide
  • Antibiotics
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Acute Pyelonephritis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acute Pyelonephritis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute Pyelonephritis drugs.

Acute Pyelonephritis Report Insights

  • Acute Pyelonephritis Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Acute Pyelonephritis Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Acute Pyelonephritis drugs?
  • How many Acute Pyelonephritis drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute Pyelonephritis?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Acute Pyelonephritis therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Acute Pyelonephritis and their status?
  • What are the key designations that have been granted to the emerging drugs?


Executive Summary

Acute Pyelonephritis: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Acute Pyelonephritis – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

  • Acute Pyelonephritis companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Acute Pyelonephritis Collaboration Deals

  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

  • Comparative Analysis

Cefepime: Venatorx Pharmaceuticals, Inc.

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

ETX2514SUL: Entasis Therapeutics

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Pre-clinical and Discovery Stage Products

  • Comparative Analysis
  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Acute Pyelonephritis Key Companies

Acute Pyelonephritis Key Products

Acute Pyelonephritis- Unmet Needs

Acute Pyelonephritis- Market Drivers and Barriers

Acute Pyelonephritis- Future Perspectives and Conclusion

Acute Pyelonephritis Analyst Views

Acute Pyelonephritis Key Companies


List of Table

Table 1: Total Products for Acute Pyelonephritis

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Acute Pyelonephritis

Figure 2: Late Stage Products                               

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products    

• Spero Therapeutics

• Iterium Therapeutics

• Nabriva Therapeutics plc.

• VenatoRx Pharmaceuticals, Inc.

• Paratek Pharmaceuticals Inc

Forward to Friend

Need A Quote